...
首页> 外文期刊>Journal of cardiovascular pharmacology and therapeutics >State of the science of cardioprotection: Challenges and opportunities-- proceedings of the 2010 NHLBI workshop on cardioprotection.
【24h】

State of the science of cardioprotection: Challenges and opportunities-- proceedings of the 2010 NHLBI workshop on cardioprotection.

机译:心脏保护科学现状:挑战与机遇-2010年NHLBI心脏保护讲习班的会议记录。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction could be altered by various interventions. Early coronary artery reperfusion has been an intervention that consistently reduces myocardial infarct size in animal models as well as humans. Most cardiologists agree that the best way to treat acute ST-segment elevation myocardial infarction is to reperfuse the infarct artery as soon as possible and to keep the infarct artery patent. In general, stenting is superior to angioplasty, which is superior to thrombolysis. There is no accepted adjunctive therapy to acutely limit myocardial infarct size along with reperfusion that is routinely used in clinical practice. In the Kloner experimental laboratory, some adjunctive therapies have reproducibly limited infarct size (regional hypothermia, preconditioning, cariporide, combinations of the above, remote preconditioning, certain adenosine agonists, and late sodium current blockade). In clinical trials, a host of pharmacologic adjunctive therapies have failed to either reduce infarct size or improve clinical outcome. Potential reasons for the failure of these trials are discussed. However, some adjunctive therapies have shown promise in data subanalyses or subpopulations of clinical trials (adenosine, therapeutic hypothermia, and hyperoxemic reperfusion) or in small clinical trials (atrial natriuretic peptide, ischemic postconditioning, and cyclosporine, the mitochondrial permeability transition pore inhibitor). A recent clinical trial with remote conditioning induced by repetitive inflation of a brachial artery cuff begun prior to hospitalization showed promise in improving myocardial salvage and there are several reports in the cardiothoracic literature, suggesting that remote preconditioning protects hearts during surgery. Thus, in 2011, there is hope that applying some of the body's own conditioning mechanisms may provide protection against ischemic damage.
机译:美国国家心肺血液研究所在2010年9月20日至21日召集了一个研讨会,“心血管保护的新视野”,以确定针对缺血和再灌注损伤的心血管保护的未来研究方向。自1970年代初以来,有证据表明,可以通过各种干预措施来改变心肌梗塞的大小。早期冠状动脉再灌注一直是一种持续减少动物模型和人类心肌梗死面积的干预措施。大多数心脏病专家一致认为,治疗急性ST段抬高型心肌梗塞的最佳方法是尽快重新灌注梗塞动脉并保持梗塞动脉专利。通常,支架置入术优于血管成形术,后者优于溶栓术。目前尚无公认的辅助治疗方法可以急性限制心肌梗塞的大小以及再灌注,这在临床实践中是常规使用的。在克罗纳(Kloner)实验实验室中,某些辅助疗法的梗塞面积可重现受限(区域性体温过低,预处理,卡立哌利特,上述药物的组合,远程预处理,某些腺苷激动剂和晚期钠电流阻滞)。在临床试验中,许多药物辅助疗法未能降低梗塞面积或改善临床结局。讨论了这些试验失败的潜在原因。但是,某些辅助疗法在临床试验的数据亚分析或亚群(腺苷,治疗性体温过低和高氧血症性再灌注)或小型临床试验(心房利钠肽,局部缺血后处理和环孢霉素,线粒体通透性转化孔抑制剂)中显示出了希望。最近的一项临床试验通过住院前开始进行肱动脉袖带的反复充气引起的远程调节,证明了改善心肌抢救的前景,心胸文献中已有几篇报道,这表明远程预处理可以在手术过程中保护心脏。因此,在2011年,人们希望应用身体自身的某些调节机制可以提供抗缺血性损伤的保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号